Home Newsfeeds Stifel Initiates Coverage On SiteOne Landscape Supply with Hold Rating, Announces Price Target of $105

Stifel Initiates Coverage On SiteOne Landscape Supply with Hold Rating, Announces Price Target of $105

Stifel analyst W. Andrew Carter initiates coverage on SiteOne Landscape Supply (NYSE:SITE) with a Hold rating and announces Price Target of $105.

byBenzinga Newsdesk

July 13, 2022

1 minute read

Stifel analyst W. Andrew Carter initiates coverage on SiteOne Landscape Supply (NYSE:SITE) with a Hold rating and announces Price Target of $105.

Navigating PayPal’s Future: Analysts Deep Dive into its Potential for Margin Improvement and Growth Leveraging Next-Generation Product Set

By Anusuya Lahiri

June 9, 2:33 PM

Wedbush analyst Moshe Katri reiterates PayPal Holdings Inc (NASDAQ: PYPL) with an Outperform and

PYPL

Apple TV+ Wants To Outshine Netflix And Disney+ With Taylor Swift’s ‘Eras Tour’ Rights

By Ananya Gairola

October 17, 6:39 AM

Apple TV+ is in contention with Netflix, Disney+, and other streaming services to secure exclusive streaming rights to Taylor Swift's highly successful "Eras Tour" concert film.

AAPL

Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial

By Benzinga Newsdesk

February 8, 10:04 AM

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the

CVKD

News

“Warner Bros. Discovery Announces ‘Olli,’ New First-Party Data Platform Powering Converged Audience Solutions”

By Benzinga Newsdesk

April 25, 11:10 AM

https://wbd.com/warner-bros-discovery-announces-olli-new-first-party-data-platform-powering-converged-audience-solutions/#:~:text=Warner%20Bros.%20Discovery%20(Nasd

WBD

Stifel Initiates Coverage On SiteOne Landscape Supply with Hold Rating, Announces Price Target of $105

Related Posts

Navigating PayPal’s Future: Analysts Deep Dive into its Potential for Margin Improvement and Growth Leveraging Next-Generation Product Set

Apple TV+ Wants To Outshine Netflix And Disney+ With Taylor Swift’s ‘Eras Tour’ Rights

Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial

“Warner Bros. Discovery Announces ‘Olli,’ New First-Party Data Platform Powering Converged Audience Solutions”